Introducing Tirzepatide in India: A New Era in Diabetes Care

Recently, the Central Drugs Standard Control Organisation (CDSCO) in India approved Eli Lilly’s Tirzepatide, an active ingredient in their well-known drugs Mounjaro and Zepbound, for diabetes treatment. While Tirzepatide () is recognized for its weight loss benefits, its approval in India is limited to managing diabetes only. This marks the first time this injectable medication will be available to Indians.

Tirzepatide Set to Launch in India in 2025, Pending Final Regulatory Approvals

Tirzepatide, administered via pre-filled pens for subcutaneous injection, is anticipated to launch in India in 2025, pending the completion of final regulatory reviews. Eli Lilly’s CEO, David Ricks, has stated that the launch depends on successful regulatory evaluations.

Diabetes Drug - Tirzepatide Gets FDA Approval for Weight Loss
Tirzepatide, a diabetes medication, is approved for weight loss management by FDA and is found to be very beneficial when combined with diet and exercise.

‘#Tirzepatide, the anti-diabetic drug helps control #appetite while enhancing #insulin sensitivity, especially in fat tissue. This dual action supports better #weightmanagement and #metabolic health. ’

Tirzepatide operates by mimicking the natural hormones gastric inhibitory polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1), which are crucial for regulating blood sugar and appetite. It enhances insulin production, reduces glucagon levels, and slows gastric emptying, helping to control hunger and support weight loss. Clinical trials have shown that Tirzepatide significantly reduces body weight and improves insulin sensitivity.

Despite its promise, Tirzepatide’s high cost and the necessity for long-term use might affect its accessibility. While existing alternatives such as Victoza are available in India, Tirzepatide offers a notable advancement in obesity and diabetes management.

The approval of Tirzepatide in India is based on extensive global clinical trials, including a substantial number of Indian participants. These trials have demonstrated its effectiveness in reducing body weight and improving metabolic health. However, ongoing monitoring will be essential to fully understand its long-term effects and cost-effectiveness.

Anti-Quick Fix Weight Loss
Trying to lose weight? Weight loss is not a race or a competition against time but a lifestyle modification. Try out some simple tips for losing weight in smart way.

Common side effects include nausea, diarrhea, and abdominal discomfort, while more serious reactions may involve pancreatitis and thyroid issues. Patients should be aware of these potential side effects and consult healthcare providers as needed.

Reference:

Tirzepatide (Subcutaneous Route) - (https://www.mayoclinic.org/drugs-supplements/tirzepatide-subcutaneous-route/description/drg-20534045)

Source-Medindia

Quiz on Weight Loss Do`s and Don`ts
Introduction Weight loss is a process that involves reducing one's body weight through various means and lifestyle adjustments. It is often pursued for health reasons, as excess weight can contribute to various health issues, including heart ...

Tirzepatide, the Anti-diabetic Drug Shows 21.1% Extra Weight Loss
Tirzepatide, approved as a Type 2 diabetes treatment, not only manages blood sugar but also promotes weight loss in individuals who are overweight.